x
Filter:
Filters applied
- My Treatment Approach
- Alexander, PhillipRemove Alexander, Phillip filter
- SVRRemove SVR filter
Keyword
- BOC1
- boceprevir1
- FDA1
- Food and Drug Administration1
- HCC1
- HCV1
- HCV RNA undetectable 4 weeks after stopping treatment1
- hepatitis C virus1
- hepatocellular carcinoma1
- HIV1
- human immunodeficiency virus1
- PEGINF1
- peginterferon1
- rapid virologic response1
- RBV1
- ribavirin1
- RVR1
- simeprevir1
- SMV1
- SOF1
- sofosbuvir1
- sustained virologic response1
- SVR-41
- TPV1
My Treatment Approach
1 Results
- Diagnosis & treatment guidelines My Treatment Approach
My Treatment Approach to Chronic Hepatitis C Virus
Mayo Clinic ProceedingsVol. 89Issue 7p934–942Published online: May 24, 2014- Mitchell L. Shiffman
- April G. Long
- Amy James
- Phillip Alexander
Cited in Scopus: 8The treatment of chronic hepatitis C virus (HCV) is evolving rapidly. In 2014, the standard of care and new backbone of HCV treatment is the polymerase inhibitor sofosbuvir (SOF). Our treatment approach in patients with HCV genotype 1 is 12 weeks of SOF, peginterferon (PEGINF), and ribavirin (RBV). In patients with cirrhosis or extrahepatic manifestations of HCV who cannot tolerate PEGINF, we use 12 weeks of SOF and simeprevir. The latter is less costly and more effective than SOF and RBV for 24 weeks.
